{"nctId":"NCT00407030","briefTitle":"IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Cervical Dystonia","startDateStruct":{"date":"2006-07"},"conditions":["Cervical Dystonia"],"count":233,"armGroups":[{"label":"incobotulinumtoxinA (Xeomin) (240 Units)","type":"EXPERIMENTAL","interventionNames":["Drug: incobotulinumtoxinA (Xeomin) (240 Units)"]},{"label":"incobotulinumtoxinA (Xeomin) (120 Units)","type":"EXPERIMENTAL","interventionNames":["Drug: incobotulinumtoxinA (Xeomin) (120 Units)"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"incobotulinumtoxinA (Xeomin) (240 Units)","otherNames":[]},{"name":"incobotulinumtoxinA (Xeomin) (120 Units)","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Main Inclusion Criteria:\n\n* Male or female outpatients between ages 18 and 75 years inclusive)\n* A clinical diagnosis of cervical dystonia (i.e. spasmodic torticollis) with predominantly rotational form and a need for injection (determined by the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) -Total score)\n* TWSTRS-Total score \\>= 20\n* TWSTRS-Severity score \\>= 10\n* TWSTRS-Disability score \\>= 3\n* TWSTRS-Pain score \\>= 1\n* On a stable dose of medications (if any) used for focal dystonia treatment (e.g. anticholinergics and benzodiazepines) for at least 3 months prior to and expected throughout the Main Period\n* For pre-treated patients only: Source documentation of the last two consecutive injection sessions with Botulinum Toxin and stable therapeutic response directly prior to trial entry\n* For pre-treated patients only: At least 10 weeks must have been passed between the last injection with Botulinum Toxin for cervical dystonia and baseline\n* For pre-treated patients only: The most recent injection with Botulinum Toxin must have been maximal 300 Units of type A or 12,000 Units of type B\n\nMain Exclusion Criteria:\n\n* Traumatic torticollis or tardive torticollis\n* TWSTRS-Severity score for anterocollis \\>= 2 points (pure anterocollis)\n* TWSTRS-Severity score for retrocollis \\>= 2 points (pure retrocollis)\n* Myotomy or denervation surgery in the affected muscles (e.g. peripheral denervation and/or spinal cord stimulation)\n* Hypersensitivity to human serum albumin, sucrose, or Botulinum Toxin Type A\n* Diagnosis of myasthenia gravis, Lambert-Eaton syndrome, amyotrophic lateral sclerosis, or any other significant neuromuscular disease which might interfere with the trial\n* Current swallowing disorder of any origin (dysphagia scale \\>= 3, i.e. severe, with swallowing difficulties and requiring a change in diet)\n* Marked limitation on passive range of motion that suggests contractures or other structural abnormality, e.g. cervical contractures or cervical spine syndrome\n* Treatment with Botulinum Toxins for any indication other than cervical dystonia within 4 months prior to baseline and during the trial","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) -Total Score at Week 4 After Injection of the Main Period - Xeomin (240 Units) Versus Placebo","description":"The TWSTRS-Total score is the sum of scores of the three components of the scale:\n\n* TWSTRS-Severity score which ranges from 0 (=absence of severity) to 35 points (=maximum severity)\n* TWSTRS-Pain score which ranges from 0 (=no pain) to 20 (=maximum pain)\n* TWSTRS-Disability score which ranges from 0 (=no disability) to 30 (=maximum disability).\n\nThe TWSTRS total score ranges from 0 (=best value) to 85 (=worst value). The change from baseline was calculated as the score at the corresponding visit minus the baseline score.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.3","spread":"2.18"},{"groupId":"OG001","value":"1.6","spread":"2.28"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the TWSTRS-Total Score","description":"The TWSTRS-Total score is the sum of scores of the three components of the scale:\n\n* TWSTRS-Severity score which ranges from 0 (=absence of severity) to 35 points (=maximum severity)\n* TWSTRS-Pain score which ranges from 0 (=no pain) to 20 (=maximum pain)\n* TWSTRS-Disability score which ranges from 0 (=no disability) to 30 (=maximum disability).\n\nThe TWSTRS total score ranges from 0 (=best value) to 85 (=worst value). The change from baseline was calculated as the score at the corresponding visit minus the baseline score.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.2","spread":"10.54"},{"groupId":"OG001","value":"-6.9","spread":"11.15"},{"groupId":"OG002","value":"0.4","spread":"7.17"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.6","spread":"7.52"},{"groupId":"OG001","value":"-3.6","spread":"8.07"},{"groupId":"OG002","value":"1.7","spread":"6.15"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the TWSTRS Disability Subscore","description":"TWSTRS-Disability score which ranges from 0 (=no disability)to 30 (=maximum disability). The change from baseline was calculated as the score at the corresponding visit minus the baseline score.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.0","spread":"4.35"},{"groupId":"OG001","value":"-3.3","spread":"4.72"},{"groupId":"OG002","value":"0.0","spread":"3.41"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.4","spread":"3.98"},{"groupId":"OG001","value":"-2.1","spread":"4.86"},{"groupId":"OG002","value":"0.8","spread":"3.27"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.3","spread":"3.13"},{"groupId":"OG001","value":"-1.4","spread":"3.82"},{"groupId":"OG002","value":"1.0","spread":"3.32"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the TWSTRS Severity Subscore","description":"TWSTRS-Severity score which ranges from 0 (=absence of severity) to 35 points (=maximum severity). The change from baseline was calculated as the score at the corresponding visit minus the baseline score.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.5","spread":"5.99"},{"groupId":"OG001","value":"-3.9","spread":"4.34"},{"groupId":"OG002","value":"-1.9","spread":"3.96"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.5","spread":"5.39"},{"groupId":"OG001","value":"-3.1","spread":"4.39"},{"groupId":"OG002","value":"-0.9","spread":"3.57"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.9","spread":"3.83"},{"groupId":"OG001","value":"-1.1","spread":"3.18"},{"groupId":"OG002","value":"-0.2","spread":"3.07"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the TWSTRS Pain Subscore","description":"TWSTRS-Pain score which ranges from 0 (=no pain) to 20 (=maximum pain). The change from baseline was calculated as the score at the corresponding visit minus the baseline score.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.4","spread":"4.36"},{"groupId":"OG001","value":"-2.7","spread":"4.55"},{"groupId":"OG002","value":"-0.3","spread":"2.97"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.3","spread":"4.32"},{"groupId":"OG001","value":"-1.8","spread":"4.15"},{"groupId":"OG002","value":"0.6","spread":"2.82"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.3","spread":"3.40"},{"groupId":"OG001","value":"-1.1","spread":"3.96"},{"groupId":"OG002","value":"0.9","spread":"2.56"}]}]}]},{"type":"SECONDARY","title":"Patient Evaluation of Global Response (PEGR) at Final Visit","description":"The PEGR is a descriptive subjective 9-point response scale ranging from \"complete abolishment of signs and symptoms\" (value=+4) down to \"very marked worsening\" (value=-4).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":"1.84"},{"groupId":"OG001","value":"1.3","spread":"1.77"},{"groupId":"OG002","value":"-0.2","spread":"1.34"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) -Total Score at Week 4 After Injection of the Main Period - Xeomin (120 Units) Versus Placebo","description":"The TWSTRS-Total score is the sum of scores of the three components of the scale:\n\n* TWSTRS-Severity score which ranges from 0 (=absence of severity) to 35 points (=maximum severity)\n* TWSTRS-Pain score which ranges from 0 (=no pain) to 20 (=maximum pain)\n* TWSTRS-Disability score which ranges from 0 (=no disability) to 30 (=maximum disability).\n\nThe TWSTRS total score ranges from 0 (=best value) to 85 (=worst value). The change from baseline was calculated as the score at the corresponding visit minus the baseline score.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.8","spread":"2.11"},{"groupId":"OG001","value":"-3.3","spread":"2.20"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) -Total Score at Week 4 After Injection of the Main Period - Xeomin (240 Units) Versus Xeomin (120 Units)","description":"The TWSTRS-Total score is the sum of scores of the three components of the scale:\n\n* TWSTRS-Severity score which ranges from 0 (=absence of severity) to 35 points (=maximum severity)\n* TWSTRS-Pain score which ranges from 0 (=no pain) to 20 (=maximum pain)\n* TWSTRS-Disability score which ranges from 0 (=no disability) to 30 (=maximum disability).\n\nThe TWSTRS total score ranges from 0 (=best value) to 85 (=worst value). The change from baseline was calculated as the score at the corresponding visit minus the baseline score.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.5","spread":"2.25"},{"groupId":"OG001","value":"-9.2","spread":"2.27"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":81},"commonTop":["Dysphagia","Neck pain","Muscular weakness","Injection site pain","Musculosceletal pain"]}}}